BofA analyst Allen Lutz lowered the firm’s price target on GoodRx (GDRX) to $4 from $4.75 and keeps an Underperform rating on the shares. GoodRx reported “a mixed, but generally good headline quarter,” beating on both revenue and EBITDA, the analyst tells investors. However, the firm lowered its price target ahead of the earnings call as it lowered its calendar year 2025 EBITDA multiple to reflect lower top-line momentum.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX:
- Strong Q1 2025 Performance and Raised EBITDA Guidance Justify Buy Rating for GoodRx Holdings
- GoodRx Holdings Faces Sell Rating Amid Decline in Consumer Growth and Cautious Revenue Outlook
- GoodRx reports Q1 adjusted EPS 9c, consensus 10c
- GoodRx sees Q2 revenue up sequentially from Q1
- GoodRx backs FY25 revenue view $810M-$840M, consensus $823.27M